Mylène Jansen

SF biomarker changes upon KJD 333 16 Figure 2 : Measurement of synovial fluid analytes during knee joint distraction. Synovial fluid from study participants immediately prior to distraction (‘baseline’), after 3 weeks of knee joint distraction (‘midpoint’) and at 6 weeks after knee joint distraction (‘endpoint’) were assayed for pre-defined markers of interest by electrochemiluminescence or ELISA (see Table I). Measurements for each of 10 analytes are shown, with mean concentrations for each analyte plotted on a log 10 y axis. * p< 0.05,** p< 0.01,*** p< 0.001 by Wilcoxon Signed Rank test, comparing paired levels at end point or midpoint versus baseline (individual p -values are given in Supplementary Table 1). (A) 6 analytes with change at endpoint versus baseline, (B) 4 analytes without change at endpoint (although upper 2 showed change at midpoint). ULN (dark dashed line) and LLN (light dashed line) of normal ranges were calculated for each analyte as described in methods and Table I. FGF-2: basic fibroblast growth factor; IL-6: interleukin 6; IL-8: interleukin 8; LLN: lower limit of normal; LLOQ: lower limit of quantification; LTBP2: latent-transforming growth factor beta-binding protein 2; MCP-1: monocyte chemoattractant protein 1; MMP3: matrix metalloproteinase-3; TGF β -1: transforming growth factor beta 1; TIMP-1: tissue inhibitor of metalloproteinases 1; TSG-6: tumour necrosis factor-inducible gene 6 protein; ULN: upper limit of normal.